8-K ·Filed Feb 25, 2026

AMRN

AMARIN CORP PLC\UK
BEARISH
Impact 6/10
Horizonweeks Processed7mo ago SEC0001193125-26-068511
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

Despite improved cost efficiency and reduced losses, the significant revenue decline is concerning. Traders should monitor whether the cost-cutting strategy can offset continued revenue pressure and whether the company can stabilize sales in international markets.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
AMRN ▲ +1.57% at T+60d
SHORT call ✗ call lost -1.57% · α vs SPY +5.38% · entry $14.05 → $14.27
Entry anchored
Feb 24, 03:59 PM ET
via exchange tick
T+1d
+0.50%
call -0.50% · α -1.04%
$14.12
settled 7mo ago
T+5d
+3.49%
call -3.49% · α -4.59%
$14.54
settled 7mo ago
T+20d
+4.48%
call -4.48% · α -9.72%
$14.68
settled 6mo ago
T+60d
+1.57%
call -1.57% · α +5.38%
$14.27
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Amarin reported Q4 2025 financial results showing a 21% year-over-year decline in total net revenue to $49.2 million, driven by lower sales in Rest-of-World and Europe. However, the company significantly reduced operating expenses by 31%, narrowing its operating loss by 88% to $6.3 million. Net loss improved to $1.2 million from $48.6 million a year ago, and cash increased to $302.6 million. The improvements were attributed to cost-saving initiatives and restructuring efforts.

Key Financial Metrics

Revenue
$49.2M
-21.0% YoY
Adj. EPS
$0.01
GAAP: $-1.20
Gross Margin
47.07%

Key Facts

  • Total net revenue decreased 21% YoY to $49.2 million in Q4 2025
  • Operating expenses decreased 31% YoY to $29.5 million
  • Operating loss narrowed 88% YoY to $6.3 million
  • Net loss improved to $1.2 million from $48.6 million in Q4 2024
  • Cash position increased to $302.6 million as of December 31, 2025
  • Revenue decline attributed to Rest-of-World sales decrease and European transition impacts

Financial Impact

Revenue decreased by $13.1 million (21%) year-over-year, while operating expenses decreased by $13.5 million (31%)

revenueoperating expensesoperating lossnet losscash

Segment Breakdown

SegmentRevenueGrowth
U.S.$41.1M-7.0%
Europe$2.3M-42.0%
Rest-of-World$3.1M-74.0%

Risk Factors

  • Continued revenue decline, particularly in international markets
  • Dependence on cost-cutting to improve financial performance
  • Transition challenges in European sales model

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-068511
Document: amrn-20260225.htm0001193125-26-068511
Document: 0001193125-26-068511-index-headers.html0001193125-26-068511
Document: 0001193125-26-068511-index.html0001193125-26-068511
Document: 0001193125-26-068511.txt0001193125-26-068511
CONTEXT: Previous Earnings (2026-02-25)0001193125-26-068511
5 reports for AMRN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AMRN — sortable, filterable
TypeNow
Aug 28, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$13.97 $13.25▼ −5.15%▼ −5.41%$12.51 (−10.45%)
Jun 4, 2026
17w ago
Court Ruling
BEARISH ★ 7/10
$13.80 $16.37▼ −18.62%▼ −20.00%$12.51 (+9.35%)
Apr 29, 2026
22w ago
8-K
NEUTRAL ★ 4/10
$14.29 $14.41▲ +0.84%▼ −5.21%$12.51 (−12.46%)
Mar 16, 2026
28w ago
Press Release
NEUTRAL ★ 4/10
$15.42 $14.55▼ −5.64%▼ −9.42%$12.51 (−18.87%)
Feb 25, 2026
31w ago
8-K
BEARISH ★ 6/10
$14.05 $14.68▼ −4.48%▼ −9.72%$12.51 (+10.96%)
Showing 5 of 5

US Market Status

Market Open — Closes in 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access